B · Normal
[Alphabet’s Isomorphic Labs is negotiating to raise approximately US$5 billion, with a valuation that may reach US$50 billion] On November 5, it was reported that Isomorphic Labs, an artificial intelligence drug research and development company owned by Alphabet, is negotiating a new round of financing and plans to raise approximately US$5 billion, with a valuation that may reach US$50 billion. Isomorphic Labs was founded in 2021 as a spin-off from Google DeepMind and is committed to using artificial intelligence to accelerate drug discovery. The company completed US$2.1 billion in financing in May this year, led by Thrive Capital, with participation from Alphabet and other investors.
Comments